May 05, 2014
A California federal judge dismissed a consolidated class action against Peregrine Pharmaceuticals Inc. for the second time on Friday, saying the suit had failed to adequately allege that the drugmaker acted recklessly by knowingly lying about its lung cancer drug.
August 26, 2013
A California federal judge tossed a consolidated class action against Peregrine Pharmaceuticals Inc. on Friday, saying the investor plaintiffs didn't adequately allege that the drugmaker and its executives knowingly lied about its lung cancer drug, causing a nosedive of the company's stock price.
October 30, 2012
Investors hit Peregrine Pharmaceuticals Inc. with multiple securities class actions last month, alleging that the drugmaker's misleading statements about its lung cancer drug later resulted in a nosedive of the company's stock price.